Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia

Abstract

Background: To assess the ejaculatory disorder caused by silodosin in the prostatic hyperplasia patients who carry out sexual actions (sexual intercourse, masturbation).

Method: The subjects of this study were 91 patients who had been clinically diagnosed to have LUTS/BPH at this hospital, who were administered silodosin at 4 mg twice a day, and who gave response to a questionnaire survey related to ejaculatory disorder. Sexual intercourse and masturbation were regarded as sexual actions in this study.

Results: Ejaculatory disorder occurred in 38 (42%) of the 91 silodosin administration cases. Forty (44%) of the 91 patients answered that they carried out sexual actions after oral intake of silodosin. When the investigation was conducted only in those who exercised sexual actions, ejaculatory disorder was observed in 38 (95%) of these 40 patients, indicating a high incidence. When asked if disturbed by the ejaculatory disorder, 29 (76%) of the 38 patients who had ejaculatory disorder answered yes. Oral silodosin was discontinued due to the ejaculatory disorder in 2 (5%) of these patients. On the whole, the discontinuation rate of oral silodosin was 2% (2/91 patients).

Conclusion: It was demonstrated that the administration of silodosin induced ejaculatory disorder at a high incidence. Since it is possible that the high frequency of ejaculatory disorder by silodosin may reduce QOL, it is considered necessary to provide sufficient information related to ejaculatory disorder at the time of treatment with silodosin.

Figure 1

Changes in IPSS and QOL score by the treatment with silodosin (n=91). *Mean ± SD. **p<0.01 by Wilcoxon signed-rank test.

Figure 2

Incidence of ejaculatory disorder in all patients and sexually active patients. Ejaculatory disorder present (fully shaded area). ejaculatory disorder absent (non shaded area).

Figure 3

Incidence of ejaculatory disorder in patients with ejaculatory disorder (n=38). On each time (fully shaded area). approx. on 2 of 3 times (slightly shaded area). approx. on 1 of 2 times (non shaded area).

Figure 4

Amount of ejaculatory semen in patients with ejaculatory disorder (n=38). Loss of semen emission (fully shaded area). decreased semen emission (non shaded area).

Figure 5

Desire to continue or discontinue the silodosin treatment in patients with ejaculatory disorder (n=38). I do not worry and want to continue the medication (fully shaded area). I worry but want to continue the medication (slightly shaded area). I worry and want to discontinue the medication (non shaded area).